Episode 131: JAK Updates for Psoriasis

Do you know JAK? If not, then you're about to. This week, we're joined by Dr. Jason Hawkes as he breaks down the specifics of JAK inhibitors, their safety profiles, the JAK-STAT pathway, and more. Each Thursday, join Dr. Raja and Dr. Hadar, board certified dermatologists, as they share the latest evidence based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Jason Hawkes, MD MS is a board-certified dermatologist and Associate Professor of Dermatology at the University of California Davis in Sacramento. He received his medical degree and completed his dermatology residency training from the University of Utah School of Medicine, where he was also enrolled in the Program's 2+2 dermatology research track. In addition to being a board-certified dermatologist, Dr. Hawkes completed a research fellowship in translation immunology at the National Institutes of Health (NIH) and received a master's degree in Clinical Investigation from Rockefeller University in NYC.   Dr. Hawkes is currently serving on the Medical Board of the National Psoriasis Foundation (NPF) and as a Councilor of the International Psoriasis Council (IPC). He is the recipient of multiple teaching awards and research grants and has served as the Principal Investigator and Co-Investigator of multiple pharmaceutical-sponsored and investigator-initiated clinical trial protocols. He is the author of more than 50 peer-reviewed publications and 8 book chapters. Dr. Hawkes' principal clinical and research interests are the treatment of complex inflammatory skin diseases, such as psoriasis, hidradenitis suppurativa, and eczema, using novel, targeted systemic or biologic therapies.   To learn more about JAK inhibitors and psoriasis, attend Dr. Hawkes' lecture at the 2022 Integrative Dermatology Symposium.